Literature DB >> 19623287

Mastocytosis: a disease of the hematopoietic stem cell.

Hans-Peter Horny, Karl Sotlar, Peter Valent, Karin Hartmann.   

Abstract

INTRODUCTION: Mastocytosis is an unusual clonal disease of the hematopoietic stem cell.
METHODS: This article is based on a selective literature search and on the authors' clinical and pathological experience.
RESULTS: The clinical manifestations of mastocytosis range from cutaneous mastocytosis, a common, prognostically favorable presentation, to mast cell leukemia, a rare, life-threatening disease. The mediator-induced symptoms usually respond well to H1 antihistamines. Therapeutic standards for cytoreduction in the progressive, systemic forms of mastocytosis are still lacking. DISCUSSION: Because some of the manifestations of mastocytosis are nonspecific and can be mimicked by other diseases, there is a risk of two types of diagnostic error: Mastocytosis may remain undiagnosed when it is actually present, or it may be diagnosed even though morphological and molecular findings rule out mastocytosis. Well-defined criteria should be used to differentiate mastocytosis from other diseases with a similar clinical presentation.

Entities:  

Keywords:  anaphylactic reaction; diagnosis; differential diagnosis; mastocytosis; urticaria

Year:  2008        PMID: 19623287      PMCID: PMC2696962          DOI: 10.3238/arztebl.2008.0686

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  28 in total

1.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

2.  The treatment of mastocytosis: an overview.

Authors:  D D Metcalfe
Journal:  J Invest Dermatol       Date:  1991-03       Impact factor: 8.551

3.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

4.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Authors:  Yongsheng Ma; Shan Zeng; Dean D Metcalfe; Cem Akin; Sasa Dimitrijevic; Joseph H Butterfield; Gerald McMahon; B Jack Longley
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

Authors:  Andres C Garcia-Montero; Maria Jara-Acevedo; Cristina Teodosio; Maria Luz Sanchez; Rosa Nunez; Aranzazu Prados; Isabel Aldanondo; Laura Sanchez; Mercedes Dominguez; Luis M Botana; Francisca Sanchez-Jimenez; Karl Sotlar; Julia Almeida; Luis Escribano; Alberto Orfao
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

Review 6.  Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

Authors:  Alexander W Hauswirth; Ingrid Simonitsch-Klupp; Martin Uffmann; Elisabeth Koller; Wolfgang R Sperr; Klaus Lechner; Peter Valent
Journal:  Leuk Res       Date:  2004-03       Impact factor: 3.156

7.  Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis.

Authors:  B S Friedman; M L Santiago; C Berkebile; D D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  1993-10       Impact factor: 10.793

Review 8.  Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Authors:  Alberto Orfao; Andrés C Garcia-Montero; Laura Sanchez; Luis Escribano
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

Review 9.  Mastocytosis: state of the art.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

10.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Authors:  Irina Maric; Jamie Robyn; Dean D Metcalfe; Michael P Fay; Melody Carter; Todd Wilson; Weiming Fu; Jennifer Stoddard; Linda Scott; Marilyn Hartsell; Arnold Kirshenbaum; Cem Akin; Thomas B Nutman; Pierre Noel; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

View more
  14 in total

1.  Re: Mastocytosis--a disease of the hematopoietic stem cell. Problematic criteria.

Authors:  Jürgen Homann; Ulrich Kolck; Gerhard J Molderings
Journal:  Dtsch Arztebl Int       Date:  2009-03-06       Impact factor: 5.594

2.  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.

Authors:  A Mayado; C Teodosio; A C Garcia-Montero; A Matito; A Rodriguez-Caballero; J M Morgado; C Muñiz; M Jara-Acevedo; I Álvarez-Twose; L Sanchez-Muñoz; S Matarraz; C Caldas; J I Muñoz-González; L Escribano; A Orfao
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

3.  Laparoscopic procedures impact on mast cell mediators, extracellular matrix and adhesion scoring system in rats.

Authors:  Hery Poerwosusanta; Ika Kustiyah Oktaviyanti; Nia Kania; Zairin Noor
Journal:  Ann Med Surg (Lond)       Date:  2020-09-02

4.  [Severe therapy refractive osteoporosis : A rare differential diagnosis].

Authors:  M Gehlen; A D Lazarescu; C Hinz; N Schmidt; M Pfeifer; M Werner; H F Weidemann; M Schwarz-Eywill; A Maier
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 5.  The differential diagnosis of food intolerance.

Authors:  Yurdagül Zopf; Hanns-Wolf Baenkler; Andrea Silbermann; Eckhart G Hahn; Martin Raithel
Journal:  Dtsch Arztebl Int       Date:  2009-05-22       Impact factor: 5.594

Review 6.  Mast cell function: a new vision of an old cell.

Authors:  Elaine Zayas Marcelino da Silva; Maria Célia Jamur; Constance Oliver
Journal:  J Histochem Cytochem       Date:  2014-07-25       Impact factor: 2.479

7.  Myelodysplasia and Mast Cell Leukemia with t(9;22).

Authors:  Kathryn J Lago; Matthew P Shupe; William N Hannah; Gopalrao V N Velagaleti; Christina Mendiola; Veronica Ortega; Brian R Haney
Journal:  Case Rep Oncol Med       Date:  2017-11-26

8.  The effect of laparoscopy on mast cell degranulation and mesothelium thickness in rats.

Authors:  Hery Poerwosusanta; Zairin Noor; Ika Kustiyah Oktaviyanti; Karyono Mintaroem; Bambang Pardjianto; Moch Aris Widodo; Edi Widjajanto
Journal:  BMC Surg       Date:  2020-05-24       Impact factor: 2.102

9.  Mastocytosis in children and adults: clinical disease heterogeneity.

Authors:  Magdalena Lange; Bogusław Nedoszytko; Aleksandra Górska; Anton Zawrocki; Michał Sobjanek; Dariusz Kozlowski
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

Review 10.  Mastocytosis: from a Molecular Point of View.

Authors:  Daniel Elieh Ali Komi; Todd Rambasek; Stefan Wöhrl
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.